144 related articles for article (PubMed ID: 36244565)
1. Tofogliflozin, a sodium-glucose cotransporter 2 inhibitor, improves pulmonary vascular remodeling due to left heart disease in mice.
Joki Y; Konishi H; Takasu K; Minamino T
J Cardiol; 2023 Apr; 81(4):347-355. PubMed ID: 36244565
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
[TBL] [Abstract][Full Text] [Related]
3. Metabolic effects of Tofogliflozin are efficiently enhanced with appropriate dietary carbohydrate ratio and are distinct from carbohydrate restriction.
Ito S; Hosaka T; Yano W; Itou T; Yasumura M; Shimizu Y; Kobayashi H; Nakagawa T; Inoue K; Tanabe S; Kondo T; Ishida H
Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29520981
[TBL] [Abstract][Full Text] [Related]
4. Association of increased hepatic insulin clearance and change in serum triglycerides or β-hydroxybutyrate concentration via the sodium/glucose-cotransporter 2 inhibitor tofogliflozin.
Matsubayashi Y; Yoshida A; Suganami H; Osawa T; Furukawa K; Suzuki H; Fujihara K; Tanaka S; Kaku K; Sone H
Diabetes Obes Metab; 2020 Jun; 22(6):947-956. PubMed ID: 31984623
[TBL] [Abstract][Full Text] [Related]
5. A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats.
Sang P; Kucherenko MM; Yao J; Li Q; Simmons S; Kuebler WM; Knosalla C
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35311828
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies: Potential roles of SGLT2 inhibitors in the management of pulmonary hypertension.
Luo T; Wu H; Zhu W; Zhang L; Huang Y; Yang X
Respir Med; 2024 Jun; 227():107631. PubMed ID: 38631526
[TBL] [Abstract][Full Text] [Related]
7. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
8. Direct Cardiac Actions of the Sodium Glucose Co-Transporter 2 Inhibitor Empagliflozin Improve Myocardial Oxidative Phosphorylation and Attenuate Pressure-Overload Heart Failure.
Li X; Lu Q; Qiu Y; do Carmo JM; Wang Z; da Silva AA; Mouton A; Omoto ACM; Hall ME; Li J; Hall JE
J Am Heart Assoc; 2021 Mar; 10(6):e018298. PubMed ID: 33719499
[TBL] [Abstract][Full Text] [Related]
9. Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry.
Sawada Y; Izumida Y; Takeuchi Y; Aita Y; Wada N; Li E; Murayama Y; Piao X; Shikama A; Masuda Y; Nishi-Tatsumi M; Kubota M; Sekiya M; Matsuzaka T; Nakagawa Y; Sugano Y; Iwasaki H; Kobayashi K; Yatoh S; Suzuki H; Yagyu H; Kawakami Y; Kadowaki T; Shimano H; Yahagi N
Biochem Biophys Res Commun; 2017 Nov; 493(1):40-45. PubMed ID: 28928093
[TBL] [Abstract][Full Text] [Related]
10. Sotatercept analog improves cardiopulmonary remodeling and pulmonary hypertension in experimental left heart failure.
Joshi SR; Atabay EK; Liu J; Ding Y; Briscoe SD; Alexander MJ; Andre P; Kumar R; Li G
Front Cardiovasc Med; 2023; 10():1064290. PubMed ID: 36910526
[TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS).
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2018 May; 20(5):1176-1185. PubMed ID: 29316236
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Syndrome Exacerbates Pulmonary Hypertension due to Left Heart Disease.
Ranchoux B; Nadeau V; Bourgeois A; Provencher S; Tremblay É; Omura J; Coté N; Abu-Alhayja'a R; Dumais V; Nachbar RT; Tastet L; Dahou A; Breuils-Bonnet S; Marette A; Pibarot P; Dupuis J; Paulin R; Boucherat O; Archer SL; Bonnet S; Potus F
Circ Res; 2019 Aug; 125(4):449-466. PubMed ID: 31154939
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin Attenuates Cardiac Remodeling in Mice Model of Cardiac Pressure Overload.
Shi L; Zhu D; Wang S; Jiang A; Li F
Am J Hypertens; 2019 Apr; 32(5):452-459. PubMed ID: 30689697
[TBL] [Abstract][Full Text] [Related]
14. Pulmonary arterial remodelling by deficiency of peroxisome proliferator-activated receptor-γ in murine vascular smooth muscle cells occurs independently of obesity-related pulmonary hypertension.
Caglayan E; Trappiel M; Behringer A; Berghausen EM; Odenthal M; Wellnhofer E; Kappert K
Respir Res; 2019 Feb; 20(1):42. PubMed ID: 30813929
[TBL] [Abstract][Full Text] [Related]
15. Selective PPARα Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis.
Murakami K; Sasaki Y; Asahiyama M; Yano W; Takizawa T; Kamiya W; Matsumura Y; Anai M; Osawa T; Fruchart JC; Fruchart-Najib J; Aburatani H; Sakai J; Kodama T; Tanaka T
Cells; 2022 Feb; 11(4):. PubMed ID: 35203369
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy.
Yerra VG; Batchu SN; Kabir G; Advani SL; Liu Y; Siddiqi FS; Connelly KA; Advani A
Cardiovasc Drugs Ther; 2022 Aug; 36(4):619-632. PubMed ID: 33886003
[TBL] [Abstract][Full Text] [Related]
17. Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice.
Mori K; Tsuchiya K; Nakamura S; Miyachi Y; Shiba K; Ogawa Y; Kitamura K
Cardiovasc Diabetol; 2019 Jun; 18(1):83. PubMed ID: 31234839
[TBL] [Abstract][Full Text] [Related]
18. Renal effects of a sodium-glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status.
Nunoi K; Sato Y; Kaku K; Yoshida A; Suganami H
Diabetes Obes Metab; 2019 Jul; 21(7):1715-1724. PubMed ID: 30945431
[TBL] [Abstract][Full Text] [Related]
19. Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice.
Pradhan K; Sydykov A; Tian X; Mamazhakypov A; Neupane B; Luitel H; Weissmann N; Seeger W; Grimminger F; Kretschmer A; Stasch JP; Ghofrani HA; Schermuly RT
Int J Cardiol; 2016 Aug; 216():85-91. PubMed ID: 27140341
[TBL] [Abstract][Full Text] [Related]
20. Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure.
Yin J; Kukucka M; Hoffmann J; Sterner-Kock A; Burhenne J; Haefeli WE; Kuppe H; Kuebler WM
Circ Heart Fail; 2011 Mar; 4(2):198-206. PubMed ID: 21216837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
